Non-specific malign stromal tumors of testis

Aim: In this study, we aimed to share our experiences about patients with miscellaneous non-specific malign stromal tumors of testis.We report the demographic and clinical characteristics and the long-term results in patients with non-specific malign stromal tumorsof testis.Material and Methods: 234 patients with testicular cancer between June 1994 and January 2019 have been evaluated retrospectively.Eleven patients (Dedifferentiated liposarcoma, Diffuse large B-cell lymphoma, Embryonal rhabdomyosarcoma, Adenocarcinomaof the epididymis, Ewing’s sarcoma of the testis, Testicular leiomyosarcoma, Well-differentiated liposarcoma, Paratesticular highgrade sarcoma and Paratesticular malignant mesothelioma) whose data were reached, are taken into the study. Patients’ age, scrotallocalization of symptoms, clinical examination findings, serum tumor marker levels, pathology results and follow-up period wererecorded.Results:The mean age at diagnosis was 43.7 years (range, 18 to 79). 54.5% of the lesions were localized to the right hemiscrotalarea and of 45.4% to the left hemiscrotal area. None of patients had a history of unilateral undescended testis in medical history ortesticular cancer in familial history. Serum tumor markers were normal in all patients. The mean scrotal mass lesion at diagnosis was59.9 mm3 (range, 33 to 138 mm3). 3 or 4 cyles of chemotherapy protocols were administered in necessary cases. Mean follow-upperiod was 80.6 months (range, 12 to 297 months). Tumor recurrence was occured in only two patients (Dedifferentiated liposarcomaand Adenocarcinoma of the epididymis) during the follow-up.Conclusion: Miscellaneous non-specific malign stromal tumors of the testis should be kept in mind especially in middle age grouppatients presented with malign scrotal lesions. Surgical treatment should be aggressive and additional specific treatment accordingto pathology result should be planned without delay. Follow-up protocols are recommended to be tumor specific.

PDF

___

1. La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010;21:1323-60.
2. Idrees MT, Ulbright TM, Oliva E, et al. The world health organization 2016 classification of testicular non-germ cell tumors: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology 2017;70:513-21.
3. Chiodini S, Luciani LG, Cai T, et al. Unusual case of locally advanced and metastatic paratesticular liposarcoma: a case report and review of the literature. Arch Ital Urol Androl 2015;87:87-89.
4. Garcia Morua A, Lozano Salinas JF, Valdes Sepulveda F, et al. [Liposarcoma of the espermatic cord: our experience and review of the literature]. Actas Urol Esp 2009;33:811-15.
5. Fitzgerald S, Maclennan GT. Paratesticular liposarcoma. J Urol 2009;181:331-32.
6. Sherman KL, Wayne JD, Chung J, et al. Assessment of multimodality therapy use for extremity sarcoma in the United States. J Surg Oncol 2014;109:395-404.
7. Kanso C, Roussel H, Zerbib M, et al. [Spermatic cord sarcoma in adults: diagnosis and management]. Prog Urol 2011;21:53-58.
8. Li F, Tian R, Yin C, et al. Liposarcoma of the spermatic cord mimicking a left inguinal hernia: a case report and literature review. World J Surg Oncol 2013;11:18.
9. Goldberg BR. Soft tissue sarcoma: An overview. Orthopaedic Nursing 2007;26:4-11.
10. Armitage JO. My treatment approach to patients with diffuse large B-cell lymphoma. Mayo Clin Proc 2012;87:161-71.
11. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007; 110:652-59.
12. Rotaru I, Nacea JG, Foarfa MC, et al. Primary diffuse large B-cell lymphoma of the testis. Rom J Morphol Embryol 2018;59:585-89.
13. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61.
14. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximabCHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14:525-33.
15. Hammond WJ, Farber BA, Price AP, et al. Paratesticular rhabdomyosarcoma: Importance of initial therapy. J Pediatr Surg 2017;52:304-8.
16. Lei WH, Wu WF, Zhen JY, et al. Alveolar paratesticular rhabdomyosarcoma mimicing epididymitis: Case report and literature review. Medicine (Baltimore) 2018;97:11164.
17. Matsumoto F, Onitake Y, Shimada K. Paratesticular Rhabdomyosarcoma Presenting With a Giant Abdominoscrotal Hydrocele in a Toddler. Urology 2016;87:200-201.
18. Arisan S, Akbulut ON, Cakir OO, et al. Primary adenocarcinoma of the epididymis: case report. Int Urol Nephrol 2004;36:77-80.
19. Zou ZJ, Xiao YM, Liu ZH, et al. Clinicopathological Characteristics, Treatment, and Prognosis of Rarely Primary Epididymal Adenocarcinoma: A Review and Update. Biomed Res Int 2017;2017:4126740.
20. Foell JL, Hesse M, Volkmer I, et al. Membraneassociated phospholipase A1 beta (LIPI) Is an Ewing tumor-associated cancer/testis antigen. Pediatr Blood Cancer 2008;51:228-34.
21. Mahlendorf DE, Staege MS. Characterization of Ewing sarcoma associated cancer/testis antigens. Cancer Biol Ther 2013;14:254-61.
22. Tanik S, Zengin K, Albayrak S, et al. Cutaneous Ewing’s sarcoma secondary to chemotherapy given for testis tumor: Case report. Int J Surg Case Rep 2014; 5:972- 74.
23. Parada D, Godoy A, Liuzzi F, et al. Primary Ewing’s sarcoma/primitive neuroectodermal tumor of the kidney. An infrequent finding. Arch Esp Urol 2007;60:321-25.
24. Mani S, Dutta D, De BK. Primitive neuroectodermal tumor of the liver: a case report. Jpn J Clin Oncol 2010;40:258-62.
25. Siraj F, Sharma S, Rai CB, et al. Primary high grade testicular leiomyosarcoma: A rare malignancy in a young male. Turk J Urol 2018;44:178-81.
26. Coleman J, Brennan MF, Alektiar K, et al. Adult spermatic cord sarcomas: management and results. Ann Surg Oncol 2003;10:669-75.
27. Khoubehi B, Mishra V, Ali M, et al. Adult paratesticular tumors. BJU Int 2002;90:707-15.
28. Adjuvant chemotherapy for localised resectable softtissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647-54.
29. da Fonseca LG, Marques DF, Takahashi TK, et al. Malignant paratesticular mesothelioma. Autops Case Rep 2014;4:45-51.